IGF::OT::IGFJOHNSON, GRAHAM:1200592 [15-007931]

NIH Blueprint for Neuroscience Research是一个由8个NIH研究所和中心组成的联盟，支持神经科学研究，建立了Blueprint Neurotherapeutics Network（BPN），作为NIH资助研究的典型终点和行业药物开发开始之间的管道。BPN为神经科学研究人员提供资金，并获得全方位的行业式药物开发服务和专业知识。该计划旨在通过I期临床试验进行药物化学优化和合同研究组织（CRO）支持的项目。每个项目都由主要开发团队（LDT）指导，该团队由主要研究者（PI）、NIH签约的行业顾问和NIH工作人员组成。该团队制定研究战略，包括里程碑，并监督CRO的实施。 NIH拥有高级、行业经验丰富的药物发现和开发顾问，他们在药物化学、药物开发、化学制造和控制（CMC）、药物代谢和药代动力学（DMPK）、毒理学、生物测定开发、法规事务、医学写作、和I期临床药理学，为BPN和其他NIH的药物发现和开发项目提供领导和技术指导药物发现和开发计划和项目。

The NIH Blueprint for Neuroscience Research, a consortium of 8 NIH Institutes and Centers that support neuroscience research, established the Blueprint Neurotherapeutics Network (BPN) as a pipeline between the typical endpoint of NIH-funded research and the beginning of industry drug development. The BPN provides neuroscience researchers with funding and access to a full range of industry-style drug development services and expertise. The program is intended for projects requiring medicinal chemistry optimization and contract research organization (CRO) support through phase I clinical trials. Each project is directed by a Lead Development Team (LDT) composed of the principal investigator (PI), industry consultants contracted by NIH, and NIH staff. This team maps out a research strategy, including milestones, and oversees implementation by CROs. The NIH possesses senior-level, industry-experienced drug discovery and development consultants with expertise in medicinal chemistry, pharmaceutical development, chemistry manufacturing and controls (CMC), drug metabolism and pharmacokinetics (DMPK), toxicology, bioassay development, regulatory affairs, medical writing, and phase I clinical pharmacology to provide leadership and technical guidance on drug discovery and development projects in the BPN and possibly other NIH drug discovery and development programs and projects.